More about

Olaparib

News
July 07, 2020
4 min watch
Save

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, <i>BRCA</i> mutations

Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

News
July 07, 2020
4 min watch
Save

Cediranib, olaparib combo not superior in ovarian cancer outside of germline mutations

Cediranib, olaparib combo not superior in ovarian cancer outside of germline mutations

Though the combination of cediranib and olaparib did not beat out platinum-based chemotherapy, it was more effective in patients with germline BRCA mutations, according to Ursula A. Matulonis, MD, of Dana Farber Cancer Institute.

News
June 24, 2020
3 min watch
Save

VIDEO: Olaparib yields ‘impressive’ results in metastatic breast cancer

VIDEO: Olaparib yields &lsquo;impressive&rsquo; results in metastatic breast cancer

In this video, Sara M. Tolaney, MD, MPH, breast medical oncologist at Dana Farber Cancer Institute, shared her perspectives on data from the TBCRC 048 trial presented during the ASCO20 Virtual Scientific Program.

News
June 15, 2020
2 min watch
Save

VIDEO: Olaparib may offer chemotherapy alternative

VIDEO: Olaparib may offer chemotherapy alternative

In this video, Halle Moore, MD, director of Breast Medical Oncology in the Department of Hematology and Oncology at Cleveland Clinic Taussig Cancer Institute, spoke with Healio about presentations in breast cancer at the virtual ASCO Annual Meeting.

News
May 20, 2020
1 min read
Save

FDA approves Lynparza for prostate cancer subset

FDA approves Lynparza for prostate cancer subset

The FDA approved olaparib for treatment of certain men with metastatic castration-resistant prostate cancer.

News
May 13, 2020
3 min read
Save

Maintenance olaparib extends OS among women with BRCA-mutated relapsed ovarian cancer

Maintenance therapy with olaparib extended OS compared with placebo among women with platinum-sensitive, BRCA-mutated relapsed ovarian cancer, according to the final analysis of the randomized phase 3 SOLO-2 study scheduled for presentation during the ASCO20 Virtual Scientific Program.

News
May 08, 2020
2 min read
Save

FDA expands Lynparza approval for gynecologic cancer

The FDA expanded the approval of olaparib to include its use in combination with bevacizumab for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.

News
April 27, 2020
4 min read
Save

Durvalumab regimen improves pathologic complete response in HER2-negative breast cancer

Durvalumab regimen improves pathologic complete response in HER2-negative breast cancer

Durvalumab and olaparib in combination with paclitaxel significantly improved pathologic complete response compared with chemotherapy alone among women with stage II or stage III high-risk, HER2-negative breast cancer, according to results of the randomized phase 2 I-SPY 2 study presented at the virtual American Association for Cancer Research Annual Meeting.

News
March 12, 2020
1 min read
Save

Phase 3 trial in relapsed ovarian cancer misses primary endpoint

Phase 3 trial in relapsed ovarian cancer misses primary endpoint

The combination of cediranib and olaparib failed to extend PFS compared with platinum-based chemotherapy for a subset of women with ovarian cancer, according to topline results of a randomized phase 3 trial.

News
January 21, 2020
1 min read
Save

FDA grants priority review to Lynparza for prostate cancer subtype

The FDA granted priority review to olaparib for the treatment of men with metastatic castration-resistant prostate cancer and homologous recombination repair gene mutations who progressed on treatment with a new hormonal agent, according to a press release from the agent’s manufacturers.

View more